may be idiopathic, associated with neurodegenerative diseases that involve the brainstem structures that regulate REM sleep, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, [1] [2] [3] [4] and it has also been described in patients with pontomesencephalic tegmentum structural lesions. 5 Idiopathic RBD may be associated with decreased striatal dopamine transporters, suggesting substantia nigra dysfunction, 6, 7 and in some patients it may precede the motor and cognitive signs of Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. 3, 4 Animals with experimental dorsolateral pontine lesions exhibit REM sleep without atonia, accompanied by vigorous behaviors that resemble those occurring in humans with RBD. 8 Thus, neuronal dysregulation or loss in the brainstem nuclei that promote REM sleep atonia, such as the locus coeruleus region or the pedunculopontine nucleus, are thought to be involved in the pathophysiology of idiopathic RBD.
INTRODUCTION

RAPID EYE MOVEMENT (REM) SLEEP BEHAVIOR DISORDER (RBD) IS A PARASOMNIA CHARACTERIZED BY VIGOROUS MOVEMENTS RELATED TO UNPLEASANT DREAMS AND LOSS
OF REM SLEEP ELECTROMYOGRAPHIC (EMG) ATONIA. 1,2 RBD may be idiopathic, associated with neurodegenerative diseases that involve the brainstem structures that regulate REM sleep, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, [1] [2] [3] [4] and it has also been described in patients with pontomesencephalic tegmentum structural lesions. 5 Idiopathic RBD may be associated with decreased striatal dopamine transporters, suggesting substantia nigra dysfunction, 6, 7 and in some patients it may precede the motor and cognitive signs of Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. 3, 4 Animals with experimental dorsolateral pontine lesions exhibit REM sleep without atonia, accompanied by vigorous behaviors that resemble those occurring in humans with RBD. 8 Thus, neuronal dysregulation or loss in the brainstem nuclei that promote REM sleep atonia, such as the locus coeruleus region or the pedunculopontine nucleus, are thought to be involved in the pathophysiology of idiopathic RBD.
Proton magnetic resonance spectroscopy ( 1 H-MRS) is a noninvasive method that allows the detection of in vivo neuronal loss and metabolic alterations in localized brain areas. The main metabolic peaks detectable with 1 H-MRS are N-acetylaspartate (NAA), creatine-phosphocreatine (Cr), choline-containing compounds (Cho) and myoinositol (mI). In brief, NAA is considered as a neuronal marker and its reduction reflects neuronal loss or damage; increased or decreased concentrations of Cho suggest membrane turnover impairment; Cr changes indicate abnormality in energy metabolism; and mI provides information concerning the glial cells. 9 1 H-MRS can detect decreased NAA/Cr ratio in the brainstem of neurodegenerative diseases such as amyotrophic lateral sclerosis 10 and spinocerebellar ataxia type 1, 11 indicating the presence of neuronal loss. The objective of our study was to evaluate whether 1 H-MRS can detect brainstem abnormalities in untreated patients with idiopathic RBD.
METHODS
Patients and Controls
We prospectively studied 15 untreated male patients with idiopathic RBD (mean age 65.7 ± 6.4 years) and 15 male age-matched healthy controls (mean age 64.3 ± 7.1 years). All patients and controls underwent a clinical sleep history, and polysomnographic (PSG), brain MRI and 1 H-MRS studies.
Patients and controls' exclusion criteria were abnormal neurologic examination, mini-mental state examination score lower than 28, use of medications known to have effect on REM sleep tonic or phasic muscle activity (eg, clonazepam, 12 antidepressants, 13 bisoprolol 14 ), and MRI abnormalities in the brainstem. A PSG apnea-hypopnea index greater than 10 was also an exclusion criterion for patients and controls, since sleep apnea has been associated with brain 1 H-MRS abnormalities. 15 All-night PSG with continuous audiovisual monitoring was recorded in all patients and controls using the standard method, including chin and left and right biceps, and anterior tibialis surface EMG recording. Sleep stages were scored according to standard criteria, 16 with the allowance for REM sleep without atonia. 12 Periodic limb movements in sleep (PLMS) were scored by standard criteria, 17 This study was approved by the ethics committee at our institution, and informed consent was obtained from each patient and control.
Brainstem Spectroscopy Evaluation
Neuroimaging studies were acquired using the 1.5 T Signa System (GE Medical Systems, Milwaukee, WI) and a quadrature head coil. The spectroscopy software operated on the 5.6 version. For each subject, long and short echo-time spectra were obtained at both the midbrain and pons (total, four spectra). Accurate voxel placement was assisted by using high-resolution (3-mm-thick with 512 x 512 pixel matrix) interleaved T2-weighted axial images. The first voxel covered the midbrain tegmentum from the posterior commissure to the isthmus rhombencephali and involved this midbrain-pontine junction to ensure inclusion of the pedunculopontine tegmental nucleus. This voxel was prescribed wide enough to embrace the ventral tegmental area and a great extent of the substantia nigra pars compacta and periaqueductal gray matter. The second voxel covered the pontine tegmentum from the isthmus rhombencephali. Its position was adjusted to the floor of the fourth ventricle to include the locus coeruleus region. Voxel volumes ranged from 3.4 to 4.3 mL (Figure 1) .
1 H-MRS consisted of a PRESS (point resolved spectroscopy) pulse sequence (TR/TE 1,600/135 msec) and a STEAM (stimulated echo acquisition mode) pulse sequence (TR/TE 1,600/20 msec, TM 13.7 msec). Both sequences involved 256 acquisitions, 2.048 data points, and 2.500-Hz spectral width, and were preceded by three chemical shift water-suppression pulses (75 Hz-bandwidth). Spectra were obtained with the automated PROBE/SV system (Single-Voxel Proton Brain Exam, GE Medical Systems). PROBE/SV performs automated adjusting of the transmitter and receiver gains, water frequency centering, magnetic field homogeneity adjusting, optimization of the water signal suppression, and localized spectrum acquisition with and without water signal suppression. Data processing and quantification were performed online by using the automated method PROBE/SVQ (GE Medical Systems), which uses a water-referencing procedure to correct B0 shifts, phase offsets, and frequency offsets of water-suppressed data. Residual water is filtered and spectra are lorentzian-to-gaussian normalized (4 Hz line-broadening). Zero-filling to 4096 data points, Fourier transformation, and a simple linear baseline correction are applied before line fitting. The main singlets: NAA, 2.01 ppm; Cho, 3.22 ppm; mI, 3.55 ppm; and Cr, 3.04 ppm, are fitted by using Marquardt curve fitting routine, and fitted amplitudes are directly used to calculate the ratios of NAA, Cho and mI to Cr.
Statistical Analysis
The Student's t-test for independent samples was used to compare peak ratios between patients and controls, and the paired Student's t-test to compare peak ratios between midbrain and pons. Patients and controls' PSG parameters were compared using the Student's t-test. A p value of <0.05 was considered significant.
RESULTS
Clinical and Polysomnographic Findings
We studied 15 untreated male patients with idiopathic RBD with a mean age of 65.7 ± 6.4 (range, 56-75) years. Mean age of RBD onset was 61 ± 7 (range, 50-73) years. Latency between RBD symptoms onset and 1 H-MRS was 5.2 ± 3 (range, 2-14)
years.
The main PSG findings in patients and controls are summarized in Table 1 , showing that there were no significant differences in the sleep architecture between patients and controls. Although 11 (73%) patients had a slow wave sleep percentage greater than 15%, the difference between patients and controls in the amount of slow wave sleep was not significant. A PLMS index greater than 10 was observed in 2 patients and 4 controls. Excessive nonperiodic limb twitching during NREM sleep was detected in 1 patient. During REM sleep, PSG disclosed excessive limb phasic EMG activity in 14 (93%) patients, excessive chin phasic EMG twitching in 10 (73%), and increased submental EMG tone in 4 (26%). Audiovisual recordings showed excessive limb and body jerking in all patients, violent behaviors in 7 (47%), and vocalizations in 8 (53%).
Brainstem Spectra in Patients and Controls
Spectra quality was generally good, and automated measurement was regularly successful with few exceptions. The most frequent measurement failure (4 cases) occurred for the midbrain myoinositol peak ( Table  2) .
Brainstem Spectra in Controls. The main metabolite peaks usually detected in other brain regions were recognized in the midbrain and in the pons. When compared to midbrain, the pontine spectra characteristically showed a relative increase in the Cho peak, and the Cho/Cr ratio was significantly greater for both the long echo time (t=5. 16 spectra from a representative control subject are shown in Figure 2 , and mean peak ratios of the control group in Table 2 . Brainstem Spectra in Patients with RBD. No significant quantitative differences in NAA/Cr, Ch/Cr and mI/Cr ratios were found between patients and controls for both echo times in both brainstem locations (Table 2) . Likewise, we found no qualitative spectra alterations in individual RBD patients or any abnormal peak (eg, lactate).
DISCUSSION
Our study shows that 1 H-MRS centered on the midbrain and pontine tegmentum does not detect significant differences in NAA/Cr, Cho/Cr, and mI/Cr ratios between untreated idiopathic RBD patients and controls.
Recently, Miyamoto et al 18 reported the case of a 69-year-old man with idiopathic RBD in whom pontine 1 H-MRS presumably detected increased Cho/Cr ratio and brainstem auditory evoked potentials showed bilateral prolongation of the III and wave V latencies, which they thought suggested neuronal dysfunction in the pons. These spectroscopic results are difficult to evaluate since they compared a single 69-yearold patient with a previously published group of 26 healthy young subjects with a mean age of 25.5 (range, 21-32) years obtained with different acquisition parameters and echo times. 19 In contrast, we assessed, using identical MRI methodology, both idiopathic RBD male patients and healthy controls matched for age, gender, and number in whom RBD and other sleep disorders were carefully excluded by PSG and clinical history. We did not perform brainstem auditory-evoked-potential studies, since this technique frequently shows normal results in patients with idiopathic RBD. 20 Our results suggest that there is no marked neuronal loss or widespread 1 H-MRS-detectable metabolic disturbance in the mesopontine tegmentum of the patients with idiopathic RBD. We cannot exclude, though, the presence of small but important functional or anatomical abnormalities in the two regions studied, since 1 H-MRS can only detect few brain metabolites and may be not sensitive enough to detect the possible neurotransmitter abnormalities related to RBD, such as a dysfunction in the monoaminergic locus coeruleus region or in the cholinergic pedunculopontine nucleus, which are structures too small to be individually studied with the spatial resolution of current 1 H-MRS. 9 Alternatively, however, our results may indicate that, in idiopathic RBD, the primary dysfunction lies elsewhere beyond the mesopontine tegmentum, probably in the pathways or centers projecting to the brainstem structures that promote REM sleep atonia, as initially hypothesized by Mahowald and Schenck. 1 Table 2 . Comparison of midbrain and pons metabolite ratios at both long and short echo time between patients with idiopathic RBD and healthy controls. (14) 1.17 0.252 SD = standard deviation; n = number of subjects; NAA = N-acetylaspartate; Cr = creatine; Cho = choline; mI = myoinositol. 
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